Conversations with AlphaGo

A N D Y O K U N & A N D R E W J AC KS O N
E dward Lasker, a chess grandmaster and Go enthusiast, is reported to have said that "the rules of Go are so elegant, organic and rigorously logical that if intelligent life forms exist elsewhere in the Universe, they almost certainly play Go". In some sense, Silver and colleagues' work proves Lasker's hypothesisit demonstrates that an inhuman intelligence plays Go in a way that is somewhat similar to human players.
The rules of Go could hardly be simpler, yet the complexity that emerges is dizzying. Human players grapple with this complexity partly by analysis: studying tactics, memorizing established patterns and learning to probe deeply into the coming moves. Professional players, who compete for millions of dollars in prize money, train from as young as four years old to master these skills. Their attainment is extraordinary -thinking a hundred moves ahead and accurately assessing the board at a glance is de rigueur. But analysis is just the foundation. Go players also have to accrue a body of wisdom and experience, rules of thumb, proverbs, strategic concepts and even a feel for the shapes that the stones (playing pieces) make. Put simply, they require judgement and intuition to play well.
AI has now met, and exceeded, the skill of the best human players. In doing so, it has posed the question of how much we really know about the game. A legendary Go player -one who changes our conceptions of the game -might come along only once in a century. When AlphaGo defeated Lee Sedol 9p (9p is the top level of accomplishment in Go), were we meeting the next legend? And would we have to throw away centuries of lore and study?
Earlier this year, an updated version of AlphaGo called AlphaGo Master played and won 60 games against top professionals. These games are still being dissected by players and fans everywhere. An additional 50 games that AlphaGo Master played against itself, released after the AI defeated the current world number one, Ke Jie 9p, are also being mined for insights into the AI's choices, particularly its opening moves.
AlphaGo Zero will now provide the next rich vein. Its games against AlphaGo Master will surely contain gems, especially because its victories seem effortless. At each stage of the game, it seems to gain a bit here and lose a bit there, but somehow it ends up slightly ahead, as if by magic. The AI's self-play games, like those of AlphaGo Master, are all-out brawls, as one would expect from two players whose judgements are identicalin perfect agreement on the stakes, neither player can give an inch.
Silver and colleagues' results suggest that centuries of human gameplay have not been wholly wrong. AlphaGo Zero independently found, used and occasionally transcended many established sequences of moves used by human players. In particular, the AI's opening choices and end-game methods have converged on ours -seeing it arrive at our sequences from first principles suggests that we haven't been on entirely the wrong track. By contrast, some of its middle-game judgements are truly mysterious and give observing human players the feeling that they are seeing a strong human play, rather than watching a computer calculate.
Go players, coming from so many nations, speak to each other with their moves, even when they do not share an ordinary language. They share ideas, intuitions and, ultimately, their values over the board -not only particular openings or tactics, but whether they prefer chaos or order, risk or certainty, and complexity or simplicity. 
CANCER TREATMENT
Bacterial snack attack deactivates a drug
Tumour cells can develop intrinsic adaptations that make them less susceptible to chemotherapy. It emerges that extrinsic bacterial action can also enable tumour cells to escape the effects of drug treatment.
C H R I ST I A N J O B I N
F rom birth, the surfaces and cavities of the human body are populated by microbes that, in tight partnership with the host, maintain a complex ecosystem that underlies many essential physiological processes 1 . One key feature of our resident microbes is their tremendous metabolic capacity. Our bacterial population contains millions of genes 2 encoding enzymes that can process substances that have been derived from nutrients or the environment, or that have been administered as drugs. Such metabolism generates other compounds that can affect host homeostasis 3 . However, microbial metabolism is not always beneficial for the host. Writing in Science, Geller et al. 4 report that bacteria within a tumour can metabolize an anticancer drug into an inactive form and thereby render it ineffective.
It was previously observed 5 that the in vitro culture of two types of human tumour cell together with non-cancerous cells called fibroblasts resulted in unexpected tumour-cell survival after treatment with the chemotherapy drug gemcitabine. Geller and colleagues carried out some detective work to investigate this phenomenon. By using DNA-sequence analysis, they found that the fibroblast sample was contaminated with a bacterium called Mycoplasma hyorhinis. Other examples of bacteria being linked to cancer treatment outcomes have been reported. For instance, people who have colorectal cancer often harbour high numbers of tumour-associated Fuso bacterium nucleatum bacteria, and this association is linked to poor clinical prognosis 6 . This bacterium can trigger the activation of a pathway in colorectal-cancer cells that results in the tumour developing resistance to the drugs fluorouracil and oxaliplatin 7 . The cytidine deaminase enzyme of M. hyorhinis might be responsible for converting gemcitabine into an inactive form through a metabolic process called deamination 8 . Geller and colleagues searched for cytidine deaminase genes in a database of bacterial genomes. The gene exists as long and short versions, and the authors found that the long version was present in around 11% of the species in the database. Of these species, more than 98% are in the bacterial class called Gammaproteobacteria, to which the model organism Escherichia coli belongs.
The authors used an E. coli strain that can detect and invade tumours to study the effect of cytidine deaminase on gemcitabine treatment. A technique called high-performance liquid chromatography-tandem mass spectro metry enabled Geller and colleagues to monitor the form of gemcitabine present in the culture medium of bacterial cells grown in vitro. When the authors deleted the long version of cytidine deaminase from E. coli, it abolished the microbe's capacity to metabolize gemcitabine into its inactive form. However, if a copy of the gene was reintroduced to the bacterium, this restored its ability to metabolize the drug.
The researchers investigated this phenomenon in vivo by analysing the effect of bacteria on gemcitabine treatment of mouse coloncancer cells that were transplanted into mice below the surface of their skin. If the animals were inoculated with E. coli, tumour growth was unaffected by the drug. However, tumours responded to gemcitabine treatment if the animals were treated with antibiotics or if the E. coli strain used lacked the long form of the cytidine deaminase gene. To test whether bacterial-mediated drug metabolism occurs in the tumour microenvironment or elsewhere in the body, the authors used a miniature device to deliver gemcitabine directly into tumours. The results were consistent with bacterial metabolic activity in the tumour microenvironment.
To determine whether this phenomenon has clinical relevance, the authors studied a human cancer called pancreatic ductal adenocarcinoma (PDAC), which is often treated with gemcitabine. In 86 out of 113 tissue samples isolated from PDAC tumours, microscopy techniques, molecular-detection approaches and sequencing analysis uncovered signs of bacterial presence. Conducting the same tests using healthy pancreatic samples revealed only rare cases (3 out of 20 samples) of bacterial tissue infiltration.
DNA sequence analysis revealed that the bacteria in PDAC samples were mainly Gammaproteobacteria from the Enterobacteriaceae family, which harbours the long form of the cytidine deaminase gene and to which E. coli belongs. The authors isolated and cultured bacteria from 15 PDAC samples. For 14 of these 15 samples, if the bacteria were cultured in vitro with human colon-cancer cells, the tumour cells were unaffected by gemcitabine administration. Together, the authors' findings are consistent with a model in which tumours are shielded from the effect of drug treatments if bacteria in the tumour microenvironment metabolize and deactivate the therapeutic agent (Fig. 1) .
Recognition of the therapeutic potential of our resident bacteria is growing. Inter actions between bacteria and immune cells are essential for the efficacy of chemotherapeutic agents including cyclophosphamide, oxali platin and cisplatin [9] [10] [11] , and for immunotherapy approaches that boost the cancer-targeting activity of the immune system 12, 13 . Geller and colleagues' work now adds another perspective to the effects of microbes on therapy, by instead demonstrating that bacteria might prevent a treatment from working.
Their findings also reveal that co-administration of antibiotics during chemotherapy might have complex consequences. For example, could antibiotics prevent cancerdrug deactivation by depleting the microbes responsible, or might they destroy beneficial organisms necessary for optimal therapeutic response? Untangling the nature of microbial networks that promote or hinder therapeutic regimens will undoubtedly open more treatment avenues for people who have cancer.
As exciting as Geller and colleagues' work is, further studies are needed before these insights result in new clinical strategies. Their model system, in which cells from cancer cell lines were transplanted into mice and high levels of E. coli were injected into the animals' bloodstream, does not reflect the natural process of cancer microenvironment formation, and might not capture how tumours are usually infiltrated by microbes. Whether microbes colonize tumours in animal pancreatic-cancer models should be explored, as well as the extent to which gemcitabine treatment is affected by microbes in such a system. Moreover, the amount of microbial biomass necessary for gemcitabine deactivation in the pancreas is unknown, so whether such a quantity could be reached in the human pancreas is unclear.
Geller and colleagues demonstrated that healthy pancreatic tissue is not readily colonized by bacteria, therefore a bacterial community is presumably not normally needed in this organ and such a presence probably reflects a pathological situation. The tumour microenvironment can generate metabolic products that are detected by sensor proteins on bacteria, activating bacterial migration into tumours 14 . Dissecting the circumstances and mechanisms leading to microbial colonization of tumours should illuminate 15 how bacteria affect tumour progression and treatment response.
Episodes of pancreatic inflammation known as pancreatitis represent a major risk Our society is crimogenic, in that our social structure produces most crime, which must therefore be regarded as one "normal" response to social stimuli. For an adequate understanding of its causation, and of appropriate remedial action, we must therefore rely primarily on sociology, with the assistance of psychology … The author makes it clear that most crime is confined to the younger age groups, is predominantly against property and not too serious, and is amenable to containment and reduction by effective community action. His prescription mainly emphasizes the desirability of a restructuring and fuller integration of the educational service in the widest sense, embracing the schools, youth service and the corrective institutions for the young. From Nature 21 October 1967 100 Years Ago I have never seen the following phenomenon described; perhaps a physiologist can give the explanation. If the eye is fixed on a stream of water for twenty or thirty seconds, and is then turned on to a fixed object, the part of the field of view that had previously been occupied by the stream appears to move in a contrary direction to that in which the water had been moving; the apparent motion slows down rapidly and ceases in from five to ten seconds. This is seen not only with lateral motion, but also with up-and-down motion, as when a stream is looked down on from a bridge. The phenomenon is perhaps best seen with running water, but it may be observed with other bodies in motion-a passing train, for instance. The effect is very curious, as only part of the field of view appears to move. From Nature 18 October 1917 factor for pancreatic cancer. It would therefore be worth determining whether bacteria are present in the pancreas during pancreatitis and, if so, whether these bacteria contribute to cancer development and possible escape from the effects of subsequent cancer drug treatment.
Changes in response to cancer treatment can be driven by several factors, including the genetic background of the tumour cells, or bacterial-induced changes to tumourcell signalling. Geller and colleagues' work adds microbial metabolism of anticancer drugs as another potential contributor to poor prognosis when tumours are treated. Although more data will be needed to firmly establish whether microbial metabolism within tumours normally affects the success of tumour treatment, the findings reveal a potential new therapeutic strategy for anticancer treatment. ■
COMPUTER SCIENCE
Data analysis meets quantum physics
A technique that combines machine learning and quantum computing has been used to identify the particles known as Higgs bosons. The method could find applications in many areas of science. See Letter p.375
ST E V E N S C H R A M M
W ith the advent of high-performance computing and the ability to process enormous amounts of data, the need for advanced data-analysis techniques continues to grow. This is particularly true for experiments at the Large Hadron Collider near Geneva, Switzerland, where particle collisions occur up to 40 million times per second 1 , generating enormous data sets. These data sets often involve only a tiny number of the particles of interest -for instance, the particles called Higgs bosons are produced approximately once every billion collisions 2, 3 . On page 375, Mott et al. 4 report a data-analysis technique that unites machine learning and quantum computing, and apply it to the problem of identifying Higgs bosons. Their approach has advantages with respect to conventional methods 5, 6 and opens up further opportunities for research.
Rare events at the Large Hadron Collider, such as the production of a Higgs boson, are identified using classifiers -combinations of variables whose values depend on the particles produced in the collisions. Classifiers need to be optimized to maximize the sensitivity of the data analysis to rare events and to reject the typically abundant background events that result from ordinary particle-physics processes. Such optimization has conventionally been achieved either by testing combinations of variables manually or by using machinelearning techniques. Each of these approaches has advantages in different situations and both were instrumental in the discovery of the Higgs boson 7, 8 in 2012. Human-constructed classifiers often have a physically intuitive meaning and can be optimized using a relatively small amount of data. However, the optimization procedure can require a substantial investment of human time. Furthermore, it rarely fully exploits correlations between variables, meaning that the data analysis is not as sensitive to the signal of interest as it could be.
By contrast, machine-learning techniques mostly need computing time rather than human time to find optimal variable combinations. In addition, they exploit both linear and non-linear correlations between variables, therefore maximizing the sensitivity of the data analysis. However, these methods require a substantial amount of data, and the optimal classifier usually does not have a clear physical meaning.
Mott and colleagues report an alternative 
